Angela L. Martinez
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.
Journal: Dermatology and therapy
Published: January 27, 2025
The role of surgery in hidradenitis suppurativa: Expert-based holistic approaches.
Journal: Clinical and experimental dermatology
Published: October 30, 2024
The role of surgery in hidradenitis suppurativa: expert-based holistic approaches.
Journal: Clinical and experimental dermatology
Published: October 30, 2024
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa.
Journal: The British journal of dermatology
Published: May 31, 2024
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 03, 2024
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Journal: The British journal of dermatology
Published: December 07, 2023
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 14, 2023
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Journal: Lancet (London, England)
Published: November 29, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026